Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionGuanylate cyclase stimulators for pulmonary hypertensionTreatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguatQuality of life in patients with chronic thromboembolic pulmonary hypertensionPulmonary hypertension: diagnostic and therapeutic challengesThe German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Chronic thromboembolic pulmonary hypertension: Medical treatment.Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.Chronic thromboembolic pulmonary hypertension.Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatmentRescue balloon pulmonary angioplasty in a rapidly deteriorating chronic thromboembolic pulmonary hypertension patient with liver failure and refractory infection.Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism.Chronic Thromboembolic Pulmonary Hypertension: Experience from a Single Center in Mexico.Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsExercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension.Integrated care and optimal management of pulmonary arterial hypertensionDiagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Pulmonary hypertension in Portugal: first data from a nationwide registry.Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.Overview of current therapeutic approaches for pulmonary hypertension.Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension.Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.Perioperative anesthesiological management of patients with pulmonary hypertension.Pulmonary arterial hypertension: an imaging review comparing MR pulmonary angiography and perfusion with multidetector CT angiography.2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.Pulmonary hypertension in Saudi Arabia: A single center experience.Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparisonDecreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension.Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.Update in pulmonary hypertension 2008.High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.Bosentan for chronic thromboembolic pulmonary hypertension.
P2860
Q24200714-AAEC0E87-4DE2-4485-BEFC-CE3ACB68DEFBQ26470534-740ED0EF-CCDC-4109-AAC5-DA53730A5453Q26746202-7C1630F7-5740-442A-97FE-BE3745E2AFAEQ26748611-E22A8769-5E5F-4E0D-A2CF-0BEDA3CA5C50Q26796434-F7EA8A6E-D8EF-427C-A390-4AE51B69133EQ27497418-E7A69B73-3C2F-40E9-9DDB-0CF41F2952E2Q27687768-9ECF90B1-4A71-44C9-A5C9-40BBECEF4C28Q30248872-B3E3DC5D-3421-43F2-BA00-21B259D97EBBQ30637782-563EE1A7-BFE4-4D6E-8BED-59ACA5EF2E2BQ33532813-77DD1671-3D65-42BF-A719-3485A30573C6Q33596457-EA21C03E-33C5-41B3-AAB9-D4AD8A78E146Q33718294-AF10AF7E-9D92-4578-9E40-40ED9C6882B6Q33720450-A5DD0999-9305-47BA-AD5A-762DBE7A05BBQ33805954-619AB167-14B0-4695-B1C1-467B5E7FBF39Q33886200-F4378B84-D93B-4FA0-84A7-EBCCBE308018Q33924397-FD12757D-CFF6-433E-84E7-ACD43AA881ADQ34179857-EBA0CD0C-21D1-42E3-9D0B-D64A30F987D9Q34195627-D1107F06-24DD-4380-BF6A-15F75392530EQ34344390-F27F9EFB-469E-4BAB-AD32-BCD1D4DC103CQ34358682-1944E8DC-C15D-4DBB-BDC0-CD8DC1A59EFBQ34417785-D4FBAA8C-CA60-40C7-A622-C5AFCAA6F501Q34425513-59FC6469-90D5-41FB-A306-6B190EF47654Q34436061-7B2F19F2-1D0B-4D9A-91FB-FAC9DB17069CQ35042377-2B3BD982-F13B-4D37-A31E-44F8FC4456F5Q35235586-6E8FD17F-98C0-4387-8082-DB88014EE1A9Q35412362-631B198B-2059-41C3-A8BC-CE07598E2E20Q36115857-DE3A7D75-C137-48AD-9CCE-9A3E0F6370C6Q36212186-6D05F03B-C1A3-4FD3-B747-68E57140C951Q36336623-E33C33E4-F629-425E-91C8-99DE6D15EF17Q36407000-B1B1DC76-20A5-47B7-AECD-AED19AA43A68Q36777766-2E72444D-2A78-4EF1-B792-1E44F2415216Q36886438-3E2A45BD-D889-4F24-8FEE-4CF5048D72BEQ36982785-8EDA60A0-E9A4-4519-AB53-3C1CDDD1ADCBQ37054498-9D9915FC-AB44-4FBF-A524-5F51A5C24188Q37209707-34E3220A-8AB6-4AD3-B829-9313118AB6B4Q37302470-AB0B0784-3B72-4803-8092-0A43D82B0913Q37356518-BEFDB8D8-B2DC-4686-8FF4-79EF5FA5B4E4Q37436774-A88A8ED9-0537-41CC-9FF3-33A24220A239Q37602928-9FBAD572-FFC9-49BB-A2E7-7883E46503A1Q37642817-A23AC6B0-C064-471C-94AA-5D0A3E01714C
P2860
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@en
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@nl
type
label
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@en
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@nl
prefLabel
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@en
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@nl
P2093
P50
P921
P1476
Bosentan for treatment of inop ...... zed, placebo-controlled trial.
@en
P2093
Adam Torbicki
Adele Morganti
Andrea M D'Armini
Bosentan Effects in iNopErable ...... onary hypertension Study Group
Eckhard Mayer
Gérald Simonneau
Irene M Lang
Lewis J Rubin
Loïc Perchenet
Marion Delcroix
P304
P356
10.1016/J.JACC.2008.08.059
P407
P577
2008-12-01T00:00:00Z